Arizona Tribune - CBD Life Sciences Inc. (CBDL) Company Online Sales Up 500%

SCOTTSDALE, AZ / ACCESS Newswire / April 10, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is thrilled to announce a 500% increase in online sales this past quarter, catapulting the company into a new phase of growth as it rides the tidal wave of a rapidly expanding global wellness economy.

This milestone reflects the company's relentless focus on innovation, clean ingredients, and product efficacy. From cutting-edge CBD topicals to adaptogenic mushroom blends, CBDL is gaining significant traction in both consumer markets and investor circles.

"We're not just selling CBD anymore," said CEO Lisa Nelson. "We're creating a new category of functional wellness - one that blends the healing powers of CBD, mushrooms, and natural ingredients backed by science and built for today's lifestyles."

Positioned in the Heart of a $7 Trillion Wellness Boom
The wellness industry is booming - valued at $7.1 trillion globally, with natural health solutions like CBD and functional mushrooms taking center stage. CBDL is uniquely positioned at this intersection, offering products that tap into two of the most explosive markets in the world:

• The CBD market, projected to exceed $60 billion by 2030

• The functional mushroom market, expected to surpass $24 billion by 2032

CBD Life Sciences Inc. is going beyond traditional CBD by launching wellness-forward formulations that include Reishi, Lion's Mane, and Ashwagandha - powerful adaptogens known for reducing stress, improving focus, boosting immunity, and fighting inflammation. The company's line of CBD Kava & Kratom Shots is also gaining momentum as a natural alternative to caffeine, energy drinks, and synthetic stress relief.

CBDL's Momentum is Just Getting Started:

• 500%+ online sales growth in Q1 2025

• Top-sellers: 3000MG Pain Relief Cream, CBD Kava & Kratom Shots, Mushroom Wellness Blends

• Retail Expansion:

  • Now selling on Walmart Marketplace

  • Products available through DoorDash in select markets

  • More e-commerce and delivery partnerships in development
    

• Innovative Product Development:

  • Proprietary Nano-CBD Technology for maximum bioavailability

  • Launch of adaptogenic mushroom products including Reishi, Lion's Mane, and Ashwagandha
    

• Domestic Production & Compliance:

  • All products made in the USA

  • Third-party tested for quality and consistency

  • Clean-label ingredients, no artificial fillers

    

For Investors
CBD Life Sciences Inc. is not just scaling - it's setting the pace. By strategically expanding into multiple billion-dollar wellness verticals, CBDL is leveraging its momentum to build a brand that is future-proof, health-focused, and ready for mass market adoption.

With more consumers turning to plant-based, functional wellness solutions every day, CBDL stands at the forefront of a generational shift in how people approach health and healing.

For investors seeking to get in on the ground floor of the next wave in natural wellness, CBD Life Sciences Inc. is the name to watch.

About CBD Life Sciences Inc.
CBD Life Sciences Inc. (CBDL) is a leading innovator in the wellness and alternative health sector, specializing in high-quality CBD and functional mushroom products designed to enhance well-being. With a commitment to scientific research and consumer safety, CBDL continues to push the boundaries of holistic health solutions, creating opportunities for exponential growth in a rapidly evolving market.

Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: [email protected]

Stay Connected & Be the First to Try Our New Functional Mushroom Products!

Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz

Mushroom Madness Website: https://www.mushroommadness.shop

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
[email protected]
4802091720

SOURCE: CBD Life Sciences, Inc.

View the original press release on ACCESS Newswire

N.Mitchell--AT